Boehringer Ingelheim has made its first investment from its corporate venturing fund launched in March in Okairòs, a Switzerland-based drug development company, which has raised €16m ($20.5m) in its series B round. The financing was led by venture capital firm Versant Ventures and joined by the €100m Boehringer Ingelheim Venture Fund. All existing investors from Okairòs’…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
